Free Trial

GSK (GSK) Stock Forecast & Price Target

GSK logo
$39.03 +1.39 (+3.69%)
Closing price 04/3/2025 03:59 PM Eastern
Extended Trading
$37.60 -1.43 (-3.66%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
7
Buy
3

Based on 10 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a strong buy rating for GSK.

Consensus Price Target

$43.25
10.82% Upside
According to the 10 analysts' twelve-month price targets for GSK, the average price target is $43.25. The highest price target for GSK is $47.00, while the lowest price target for GSK is $39.50. The average price target represents a forecasted upside of 10.82% from the current price of $39.03.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up

GSK Analyst Ratings Over Time

TypeCurrent Forecast
4/4/24 to 4/4/25
1 Month Ago
3/5/24 to 3/5/25
3 Months Ago
1/5/24 to 1/4/25
1 Year Ago
4/5/23 to 4/4/24
Strong Buy
3 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
3 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$43.25$43.25$43.25N/A
Forecasted Upside10.82% Upside11.51% Upside29.22% UpsideN/A
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Remove Ads

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.81
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside10.82% Upside19,388.82% Upside25.02% Upside
News Sentiment Rating
Neutral News

See Recent GSK News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/12/2025Morgan Stanley
3 of 5 stars
 Initiated CoverageEqual Weight
11/15/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 DowngradeBuy ➝ Hold
11/12/2024Jefferies Financial Group
2 of 5 stars
 DowngradeBuy ➝ Hold$53.00 ➝ $39.50+8.64%
10/31/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Fernandez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
8/27/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Field
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/7/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hauber
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/20/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Holford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$47.00+6.12%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageReduce

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:35 AM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, March 29, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc has recently received a "strong-buy" rating from StockNews.com, indicating strong confidence from analysts in the company's future performance.
  • The stock is currently trading at $38.28, which is near its 1-year high of $45.93, suggesting potential for growth as it approaches previous highs.
  • Institutional investors own 15.74% of GSK plc's stock, which can indicate stability and confidence in the company's long-term prospects.
  • Recent increases in stakes by various hedge funds, such as Corient Private Wealth LLC raising its position by 12.8%, reflect positive sentiment and potential for future growth.
  • GSK plc has a market capitalization of $79.24 billion, which positions it as a significant player in the pharmaceutical industry, providing a level of security for investors.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • The stock has experienced fluctuations, with a recent trading down of 0.8%, which may indicate volatility and uncertainty in the market.
  • GSK plc has a P/E ratio of 24.08, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
  • Despite recent positive ratings, seven analysts have rated the stock with a hold rating, indicating caution among some market experts.
  • The company's debt-to-equity ratio stands at 1.12, which may raise concerns about its financial leverage and ability to manage debt effectively.
  • Recent changes in institutional holdings, such as Envestnet Portfolio Solutions Inc. decreasing its stake by 13.7%, could signal a lack of confidence from some investors.

GSK Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $43.25, with a high forecast of $47.00 and a low forecast of $39.50.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 7 hold ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GSK shares.

According to analysts, GSK's stock has a predicted upside of 10.82% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Morgan Stanley in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.60 while the average consensus rating score for "medical" companies is 2.82. Learn more on how GSK compares to other companies.


This page (NYSE:GSK) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners